Centralised Full Access to Clinical Study Data Can Support Unbiased Guideline Development, Continuing Medical Education, and Patient Information. [PDF]
J Eur CME, 2021 McGauran N, Wieseler B.
europepmc +1 more source
Preferences for and use of oral anticoagulants for stroke prevention in atrial fibrillation under real-world conditions in Germany: A survey among physicians. [PDF]
Prev Med Rep, 2022 Mocek A +4 more
europepmc +1 more source
Pathing the way from regulatory approval to market access for gene therapy products (GTPs): An integrative review in the US, EU5, Japan and China. [PDF]
Regen TherShi J, Hu H, Ung COL.
europepmc +1 more source
Comment on: "10 Years of AMNOG: What is the Willingness-to-Pay for Pharmaceuticals in Germany?" [PDF]
Appl Health Econ Health PolicyGandjour A.
europepmc +1 more source
Authors' Reply to Gandjour: "10 Years of AMNOG: What is the Willingness-to-Pay for Pharmaceuticals in Germany?" [PDF]
Appl Health Econ Health PolicyBüssgen M, Stargardt T.
europepmc +1 more source
Fampridin laut AMNOG erstattungsfähig [PDF]
DNP - Der Neurologe und Psychiater, 2013 openaire +1 more source
Primary endpoint acceptance and its association with benefit ratings and market access in German health technology assessments: a retrospective cohort study. [PDF]
Lancet Reg Health EurMüller G, Granold M, Busse R, Hahn A.
europepmc +1 more source